MARKET

AGLE

AGLE

Aeglea Bio
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.720
-0.480
-9.23%
Closed 16:04 03/27 EDT
OPEN
4.830
PREV CLOSE
5.20
HIGH
4.930
LOW
4.600
VOLUME
42.11K
TURNOVER
--
52 WEEK HIGH
9.10
52 WEEK LOW
3.500
MARKET CAP
137.28M
P/E (TTM)
-1.9286
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of AGLE and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average AGLE stock price target is 17.86 with a high estimate of 26.00 and a low estimate of 10.00.

EPS

AGLE News

More
  • Does Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Have A Particularly Volatile Share Price?
  • Simply Wall St. · 19h ago
  • The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO
  • Benzinga · 03/12 11:37
  • The Daily Biotech Pulse: NY State Endorses Mallinckrodt's Opioid Settlement, Kamada To Work On COVID-19 Treatment
  • Benzinga · 03/11 12:05
  • The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index
  • Benzinga · 03/10 13:19

Industry

Biotechnology & Medical Research
-2.43%
Pharmaceuticals & Medical Research
-0.87%

Hot Stocks

Symbol
Price
%Change

About AGLE

Aeglea BioTherapeutics, Inc. is a biotechnology company engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. Its lead product candidate, pegzilarginase, is engineered to degrade the amino acid arginine and is being developed to lower arginine levels in patients with Arginase I Deficiency. Its AEB4104 product candidate is a recombinant human enzyme that degrades the amino acid homocysteine and its oxidized form homocystine. It is developing AEB4104 for the treatment of patients with cystathionine beta synthase (CBS) deficiency. Its AEB5100 products candidate is a recombinant human enzyme that degrades plasma cystine and cysteine. It is developing AEB5100 product candidate for the treatment of patients with cystinuria. Its AEB3103 product candidate is an engineered human enzyme that targets the degradation of the amino acid cysteine/cystine.
More

Webull offers kinds of Aeglea Bio Therapeutics Inc stock information, including NASDAQ:AGLE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AGLE stock news, and many more online research tools to help you make informed decisions.